ArticleMetabolic brain disease2015
Antidepressant-like effects of ferulic acid: involvement of serotonergic and norepinergic systems.
Article in Metabolic brain disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 80 citations in OpenAlex.
- Wild Flora Species from Romania with Anxiolytic and Antidepressant Potential: A Global Perspective-Narrative Review.Biomedicines · 2026Review
- Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy.Frontiers in nutrition · 2026Review
- A Bibliometric Analysis of Research on Natural Medicines for Depression from 2004 to 2024.Journal of multidisciplinary healthcare · 2025Article
- Ferulic Acid-Loaded Nanostructure Maintains Brain Levels of ACh, Glutamate, and GABA and Ameliorates Anxiety and Memory Impairments Induced by the D-Galactose Aging Process in Rats.Neurochemical research · 2024Article
- A Comprehensive Review of the Pharmacological Effects of Genus Ferula on Central Nervous System Disorders.Central nervous system agents in medicinal chemistry · 2024Review
- Therapeutic potential ofFrontiers in pharmacology · 2024Review
- Anxiolytic-Pharmaceuticals (Basel, Switzerland) · 2023Article
- Ferulic acid as a therapeutic agent in depression: Evidence from preclinical studies.CNS neuroscience & therapeutics · 2023Review
- Rational Design of Multifunctional Ferulic Acid Derivatives Aimed for Alzheimer's and Parkinson's Diseases.Antioxidants (Basel, Switzerland) · 2023Article
- Tao-Hong-Si-Wu decoction improves depressive symptoms in model rats via amelioration of BDNF-CREB-arginase I axis disorders.Pharmaceutical biology · 2022Article
- Polyphenols and Their Nanoformulations: Protective Effects against Human Diseases.Life (Basel, Switzerland) · 2022Review
- Phenolic Acids as Antidepressant Agents.Nutrients · 2022Review
- Neuroprotective Natural Products' Regulatory Effects on Depression via Gut-Brain Axis Targeting Tryptophan.Nutrients · 2022Review
- Phenolic Acids and Prevention of Cognitive Decline: Polyphenols with a Neuroprotective Role in Cognitive Disorders and Alzheimer's Disease.Nutrients · 2022Review
- Nutraceuticals and Physical Activity as Antidepressants: The Central Role of the Gut Microbiota.Antioxidants (Basel, Switzerland) · 2022Review
- The GenusFrontiers in pharmacology · 2022Review
- Chinese Herbal Medicine in the Treatment of Depression in Parkinson's Disease: From Molecules to Systems.Frontiers in pharmacology · 2022Review
- Biologically Active Compounds Present in Tobacco Smoke: Potential Interactions Between Smoking and Mental Health.Frontiers in neuroscience · 2022Review
- Recent Advances in Biological Activity, New Formulations and Prodrugs of Ferulic Acid.International journal of molecular sciences · 2021Review
- Plant Polyphenols for Aging Health: Implication from Their Autophagy Modulating Properties in Age-Associated Diseases.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferulic acid is a polyphenol that has antioxidant, anti-inflammatory and anticancer properties. The present study analyzed the antidepressant-like potential of ferulic acid using two well-validated mouse models of despair test, tail suspension and forced swim tests. The results suggested that ferulic acid treatment at doses of 10, 20, 40 and 80 mg/kg (p.o.) significantly reduced the immobility time in both of these two tests. These doses that affected the depressive-like behaviors did now show any effect on locomotion counts. The further neurochemical assays suggested that ferulic acid increased monoamine neurotransmitter levels in the brain regions that are relative to mood disorders: the hippocampus and frontal cortex. The increased tend to serotonin and norepinephrine was also found in the hypothalamus after higher dose of ferulic acid treatment. The subsequent study suggested that monoamine oxidase A (MAO-A) activity was inhibited in the frontal cortex and hippocampus when treatment with 40 and 80 mg/kg ferulic acid; while MAO-B activity did not change significantly. The current study provides the first lines of evidence that serotonin and norepinephrine, but not dopamine levels were elevated in mouse hippocampus and frontal cortex after ferulic acid treatment. These changes may be attributable to the inhibition of MAO-A activities in the same brain regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.